Hospital
Alegent Health Community Memorial Hospital of Missouri Valley, Iowa
Alegent Health Community Memorial Hospital of Missouri Valley, Iowa was paid $1.39M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is 99283, emergency room visit (moderate) — 42% of everything it billed.
33Billing provider infoALEGENT HEALTH COMMUNITY MEMORIAL HOSPITAL OF MISSOURI VALLEY, IOWA
MISSOURI VALLEY, IA 51555
MISSOURI VALLEY, IA 51555
33aNPI1508964123assigned 09/20/2006
33bProvider typeCritical Access Hospital
28Total paid$1.39M
24GClaims25,872
24DCodes billed40
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Iowa
Rank by total paid#27 of 79
Median peer was paid$801K
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KUIPER, EVERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,326 | $168K | |
| 2019 | 3,261 | $160K | |
| 2020 | 3,685 | $131K | |
| 2021 | 3,068 | $145K | |
| 2022 | 3,972 | $240K | |
| 2023 | 4,506 | $286K | |
| 2024incomplete | 4,054 | $260K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 42% | 5,461 | 4,428 | $585K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 1,362 | 1,089 | $244K |
| 80053 | Comprehensive metabolic panel | 12% | 4,658 | 4,105 | $164K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.2% | 4,796 | 4,190 | $100K |
| 36415 | Collection of venous blood by venipuncture | 4.3% | 3,010 | 2,441 | $60K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 588 | 553 | $30K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 164 | 99 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 482 | 391 | $29K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.8% | 1,675 | 796 | $26K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.4% | 184 | 177 | $20K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 1.1% | 12 | 12 | $15K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 729 | 691 | $12K |
28 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 376 | $9K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 74 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 151 | $6K |
| 80050 | General health panel | <1% | 46 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 89 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 113 | $5K |
| 80061 | Lipid panel | <1% | 192 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 197 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 423 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 138 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 74 | $4K |
| 84484 | <1% | 106 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 73 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 105 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 46 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $2K |
| J3490 | Unclassified drugs | <1% | 226 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 53 | $794.80 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 13 | $777.89 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 53 | $760.81 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 14 | $681.92 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 29 | $611.63 |
| 83605 | <1% | 38 | $398.88 | |
| 86140 | <1% | 14 | $247.57 | |
| 86803 | <1% | 12 | $221.60 | |
| 81001 | <1% | 34 | $206.33 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 36 | $119.00 |
| 85610 | <1% | 13 | $95.76 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKUIPER, EVERT (CEO - CHI HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.